Inovio Pharmaceuticals, Inc. (INO): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of INO were reported in the last 12 months. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Inovio Pharmaceuticals
From the latest filingsOverall: more buying than selling. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns INO
101 funds and institutions reported INO shares worth $36.1M at the end of Q2 2026, about 47% of the company. The largest holder is FMR LLC (Fidelity) with 12.2%.
Funds and institutions (13F) 47%Everyone else 53%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 8.45M | 12.24% | $9.3M | -9% |
| Jupiter Topco LLC | 5.17M | 7.48% | $5.7M | New |
| Vanguard Capital Management LLC | 3.65M | 5.28% | $4M | +26% |
| Boxer Capital Management, LLC | 2.84M | 4.12% | $3.1M | +20% |
| ADAR1 Capital Management, LLC | 2.14M | 3.10% | $2.4M | +46% |
| D. E. Shaw & Co., Inc. | 1.35M | 1.96% | $1.5M | -39% |
| Two Sigma Investments, LP | 1.24M | 1.79% | $1.4M | +218% |
| Eversept Partners, LP | 1.04M | 1.50% | $1.1M | No change |
| Geode Capital Management, LLC | 802,751 | 1.16% | $884K | +0% |
| Millennium Management LLC | 796,107 | 1.15% | $876K | -44% |
| BlackRock, Inc. | 779,057 | 1.13% | $857K | +18% |
| Vanguard Fiduciary Trust Co | 480,769 | 0.70% | $529K | +23% |
| Caption Management, LLC | 478,950 | 0.69% | $527K | New |
| Renaissance Technologies LLC | 361,339 | 0.52% | $397K | -44% |
| State Street Corp | 336,610 | 0.49% | $370K | +14% |
| Gsa Capital Partners LLP | 265,011 | 0.38% | $292K | No change |
| UBS Group AG | 262,320 | 0.38% | $289K | +5% |
| Quadrature Capital Ltd | 258,928 | 0.37% | $285K | New |
| Citadel Advisors LLC | 241,775 | 0.35% | $266K | -16% |
| Northern Trust Corp | 174,394 | 0.25% | $192K | -42% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No INO insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
INO short interest
Very high short interest. 21.4% of INO shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 38%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 22.10M INO shares were sold short, 21.4% of the shares outstanding, up 3.7% from the report before. At the average daily volume of 12.15M shares, buying them all back would take about 1.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 22.10M | 21.37% | +4% | 12.15M | 1.8 |
| Oct 15, 2026 | 21.30M | 20.60% | +2% | 3.07M | 6.9 |
| Sep 30, 2026 | 20.82M | 20.13% | +4% | 2.74M | 7.6 |
| Sep 15, 2026 | 19.92M | 19.27% | +3% | 3.05M | 6.5 |
| Aug 31, 2026 | 19.25M | 18.62% | -4% | 4.42M | 4.4 |
| Aug 14, 2026 | 19.96M | 19.31% | +24% | 5.35M | 3.7 |
| Jul 31, 2026 | 16.04M | 23.22% | +10% | 5.12M | 3.1 |
| Jul 15, 2026 | 14.57M | 21.09% | -3% | 1.59M | 9.2 |
| Jun 30, 2026 | 15.04M | 21.77% | -7% | 1.44M | 10.4 |
| Jun 15, 2026 | 16.20M | 23.45% | -0% | 1.50M | 10.8 |
| May 29, 2026 | 16.27M | 23.55% | +2% | 2.80M | 5.8 |
| May 15, 2026 | 15.98M | 23.13% | +12% | 5.05M | 3.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Inovio Pharmaceuticals company events
Inovio Pharmaceuticals filed 15 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Nov 9, 2026AgreementInovio Pharmaceuticals, Inc. entered into an underwriting agreement with Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein, relating to the issuance and sale by the Company in a public offering of 58,747,235 shares of the Company’s common stock, par… Filing
- Nov 5, 2026ResultsReleased financial results. Filing
- Nov 2, 2026AnnouncementBelow, on October 30, 2026, Inovio Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted accelerated approval for VOCERYQ ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, to reduce the… Filing
- Oct 6, 2026RulesChanged its bylaws or articles. Filing
- Aug 12, 2026ResultsReleased financial results. Filing
- Jul 31, 2026AgreementInovio Pharmaceuticals, Inc. entered into an underwriting agreement with Piper Sandler & Co., as underwriter, relating to the issuance and sale by the Company in a public offering of (i) 21,052,632 shares of the Company’s common stock, par value $0.001 per share, and (ii) accompanying warrants to… Filing
- Jul 29, 2026ResultsReleased financial results. Filing
- May 20, 2026VoteReported shareholder vote results. Filing
- May 13, 2026ResultsReleased financial results. Filing
- Apr 6, 2026AgreementInovio Pharmaceuticals, Inc. entered into an underwriting agreement with Piper Sandler & Co., as representative of the several underwriters named therein, relating to the issuance and sale by the Company in a public offering of 12,500,000 shares of the Company’s common stock, par value $0.001 per… Filing
- Apr 2, 2026AnnouncementOn April 1, 2026 Inovio Pharmaceuticals, Inc. notified Oppenheimer & Co. Inc. that it was suspending and terminating the prospectus, dated August 13, 2024, related to the sales agreement that the Company entered into with the Sales Agent on August 13, 2024 and pursuant to which the Company may… Filing
- Mar 12, 2026ResultsReleased financial results. Filing
- Jan 27, 2026AgreementInovio Pharmaceuticals, Inc. amended each of its outstanding Series A warrants issued on July 7, 2025 to extend the expiration date of each outstanding Series A Warrant to 5:00 p.m. Filing
- Dec 29, 2025AnnouncementBelow, on December 29, 2025, Inovio Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has accepted the Company’s Biologic License Application for INO-3107, an investigational immunotherapy for the treatment of recurrent respiratory papillomatosis in… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Inovio Pharmaceuticals financials
Famous investors that hold INO
4 of the 50 well-known investors we track reported holding INO in their latest 13F filing. The largest position is Ken Griffin's, worth $3.8M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 3.13M | $3.8M | 0.0% | +1193% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.51M | $1.8M | 0.0% | +319% |
| Israel Englander · Millennium Management | Q3 2026 | 97,963 | $120K | 0.0% | -88% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 11,868 | $14.5K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named INO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | ADAR1 Capital Management, LLC | 13G | 7.4% |
| Nov 16, 2026 | ADAR1 Capital Management, LLC | 13G | 7.4% |
| Nov 16, 2026 | TANG CAPITAL MANAGEMENT, LLC | 13G | 10.0% |
| Nov 16, 2026 | TANG CAPITAL MANAGEMENT, LLC | 13G | 10.0% |
| Nov 16, 2026 | Alyeska Investment Group, L.P. | 13G/A | 3.3% |
| Nov 16, 2026 | Highbridge Capital Management, LLC | 13G/A | 9.9% |
| Nov 16, 2026 | Highbridge Capital Management, LLC | 13G/A | 9.9% |
| Nov 16, 2026 | Alyeska Investment Group, L.P. | 13G/A | 3.3% |
| Nov 5, 2026 | FMR LLC | 13G/A | 14.5% |
| Nov 5, 2026 | FMR LLC | 13G/A | 14.5% |
Questions about Inovio Pharmaceuticals, Inc. (INO) stock
Who owns the most INO stock?
The largest reported owner of Inovio Pharmaceuticals, Inc. (INO) is FMR LLC (Fidelity), with 12.2% of the company. In total, 101 funds and institutions reported holding INO at the end of Q2 2026, together about 47% of the shares. See the largest owners.
Are INO insiders buying or selling?
No INO insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in INO?
As of Oct 30, 2026, 22.10M INO shares were sold short, 21.4% of the shares outstanding, up 3.7% from the report before. At the average daily volume of 12.15M shares, buying them all back would take about 1.8 trading days (days to cover). See the history.
Which famous investors hold INO?
4 of the 50 well-known investors we track reported INO in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $3.8M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.